Rise in vaccine costs "put children at risk"

22 April 2007

The American Academy of Pediatrics has issued a warning that "soaring costs" of vaccines and lower reimbursement levels from insurers will cause the "under-immunization" of the USA's children.

Jay Berkelhamer, the AAP's president, said that "the system for delivering vaccines is broken and we're going to be in real trouble if it's not fixed soon."

The 60,000-member group argues that pediatricians face delays in receiving payments from both Medicaid and private heath plans, leaving them out-of-pocket by thousands of dollars for several months at a time. To make matters worse, payments often do not cover the products' cost. Gardasil, US drug major Merck & Co's cervical cancer vaccine, costs $360 per treatment course and the same firm's Rotateq vaccine against rotavirus costs $190. Some pediatricians are therefore refusing to stock the newest vaccines, according to the AAP. Jon Almquist, the group's immunization task force chairman, said: "we shouldn't be expected to subsidize the public health system and perform our jobs at a loss."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight